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PDT as a Cytotoxic Agent and 
Biological Response Modifier: 
Implications for Cancer Prevention 
and Treatment in Immunosuppressed 
and Immunocompetent Patients
Allan Oseroff1
PDT acts as a biological response modifier in addition to directly damaging tar-
get cells and their blood supply. The reduced efficacy of PDT in immunosup-
pressed patients demonstrates the importance of immune mechanisms in this 
therapy, and transplant recipients require aggressive optimization of direct 
cytotoxic pathways. However, immunocompetent individuals can benefit from 
PDT's effects on innate and adaptive immune responses, including the possibil-
ity of generating in situ anti-tumor vaccines.
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With an annual incidence of more than 
one million new cancers and many 
more actinic keratoses (AKs), the skin 
has far more malignancies and pre-
malignancies than any other organ. Yet 
without immune surveillance, the inci-
dence could be much greater: lack of 
immune response is largely responsible 
for the plight of immunosuppressed 
solid-organ-transplant recipients, who 
have 10–250-fold increased rates of 
AKs, and basal and squamous-cell car-
cinomas (BCC and SCC) that may be 
very aggressive (Euvrard et al., 2003; 
Berg and Otley, 2002). To add addi-
tional injury to insult, immunosuppres-
sive therapies also may directly promote 
cancers (Berg and Otley, 2002): for 
example, a recent paper in this journal 
showed that calcineurin inhibitors such 
as cyclosporine inhibit thymidine dimer 
removal and UVB-induced apoptosis 
(Yarosh et al., 2005), and azathioprine 
sensitizes UVA-induced oxidative DNA 
damage (O’Donovan et al., 2005).
Conventional therapies are prob-
lematic for transplant recipients and for 
other individuals with large numbers of 
carcinomas from nevoid basal cell car-
cinoma syndrome (NBCCS), xeroderma 
pigmentosum, or excessive sun expo-
sure. It would thus be desirable to have 
means to treat large numbers of lesions 
or, preferably, to eliminate subclinical 
disease before it can become overt.
Photodynamic therapy (PDT) with 
topical 5-aminolevulinic acid (ALA) or 
its methyl ester is a non-scarring modal-
ity that can be applied to large areas of 
the skin. In immunocompetent patients, 
topical PDT has proved quite effective 
for treating AK, Bowen’s disease and 
thin BCC (reviewed in Morton et al., 
2002), and it is efficacious for children 
with extensive NBCCS (Oseroff et al., 
2005). Is PDT also beneficial for trans-
plant recipients?
In 2004 Dragieva and colleagues 
reported an open, prospective trial of 
ALA-PDT treatment of AK and Bowen’s 
disease in both immunosuppressed and 
immunocompetent patients (Dragieva, 
2004). One to six small areas averaging 
12 cm2 were treated per patient, with 
one or two treatments 1 week apart 
using red light. Initial clinical response 
rates of the two groups of patients at 4 
weeks were similar (88% in transplant 
recipients versus 94% in controls), but 
by 48 weeks the transplant recipients 
had dropped to only a 48% response 
rate, compared with 72% in the immu-
nocompetent patients. Body site made 
a difference: in transplant recipients, 
for AK on the scalp, face and neck, the 
respective 4 and 48 week complete 
response rates were 96% and 52%, 
respectively, whereas for AK treatment 
fields on the hands and arms, the 4 and 
48 week complete response rates were 
only 55% and 9%. Thus, although there 
was site-dependent benefit in immu-
nosuppressed patients, there also was 
clear persistence of residual disease or 
recurrence of new lesions, relative to 
immunocompetent controls.
In this issue, a paper by de Graaf et al. 
(2006) reports an ambitious randomized, 
controlled trial involving paired observa-
tions of the back of the hands and entire 
forearms of 40 transplant recipients with 
extensive keratoses, examining chang-
es in the number of keratoses over 12 
months and the incidence of SCC over 
2 years. The trial involved treatment to 
one hand and forearm, with the other 
side serving as a control. All patients 
received an initial PDT treatment with 
a blue light, and half received a second 
treatment after 6 months.
In contrast to the results of Dragieva 
et al., there was essentially no effect on 
the number of keratotic lesions 4 and 8 
weeks after the first PDT treatment, and 
only a modest change after the second. 
There were no differences in the inci-
dence of SCC between the treated and 
untreated arms. What does one make of 
the negative outcomes, taken together 
with the limited durability of the earlier 
work? The studies bring up important 
issues regarding underlying mecha-
nisms and techniques of PDT in immu-
nocompetent and suppressed patients, 
and set useful thresholds for this modal-
ity in transplant recipients.
Mechanisms of PDT
PDT is a three-component process 
involving a photosensitizing drug, light, 
and oxygen. Light absorption by the 
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photosensitizer produces an excited 
triplet state that transfers its energy to 
oxygen, forming highly reactive, cyto-
toxic singlet oxygen (Dougherty et al., 
1998). The sensitizer molecule can then 
absorb another photon and repeat the 
process, generating singlet oxygen in an 
almost catalytic fashion until the mol-
ecule is destroyed (photobleached) by 
auto-oxidation. Topical ALA-PDT does 
not involve administration of an exog-
enous photosensitizer. Instead, ALA 
bypasses the checkpoint in the heme 
synthetic pathway, leading to transient 
accumulation of the endogenous pho-
tosensitizer protoporphyrin IX (PpIX) 
as long as the rate of ALA → PpIX is 
greater than the rate of PpIX → heme 
(Rittenhouse-Diakun et al., 1995). 
Accumulation occurs in carcinomas, 
epidermally derived cells, mast cells, 
activated lymphocytes, dendritic cells, 
and monocytes, but not in mesenchy-
mally derived cells (Rittenhouse-Diakun 
et al., 1995). PDT acts through multiple 
mechanisms, including through vascu-
lar shutdown, by direct killing of target 
cells, and as a biological response mod-
ifier via induction of innate and adap-
tive host immune responses.
Microvascular shutdown is an 
important component of systemic PDT, 
where intravascular photosensitizer 
follows a gradient from the circulation 
to endothelial and periendothelial cells 
on the way to the tumor. With topical 
PDT and in situ PpIX synthesis, the gra-
dient is reversed and the endothelium 
protected. Microvascular shutdown 
gives enormous leverage in target cell 
killing through downstream oxygen 
and nutrient deprivation, albeit at the 
expense of selectivity and scarring. 
Without microvascular occlusion, topi-
cal ALA-PDT gains selectivity at the 
expense of efficacy.
Direct cell killing can occur 
through both apoptosis and necrosis. 
Mitochondrial injury, damage to Bcl-2, 
and activation of phospholipases C and 
A2, among other processes, drive apop-
totic pathways. Simultaneously, oxi-
dative damage to membrane proteins 
and lipids and to cytoplasmic proteins, 
and the loss of intracellular energy 
supplies, induce stress responses and 
necrosis. The balance between apop-
tosis and necrosis depends on the cell 
type, photosensitizer, and irradiation 
conditions (Dougherty et al., 1998). 
Cell killing depends on the amount of 
singlet oxygen, which is proportional to 
the product of the local concentration 
of PpIX and the dose of absorbed light. 
However, PpIX is relatively easily photo-
bleached (auto-oxidized) during illumi-
nation, so it can be the limiting factor in 
singlet oxygen production. Once PpIX 
and its photoproducts are completely 
bleached, additional photoillumination 
is not effective, which limits the amount 
of singlet oxygen that can be produced. 
Thus, to maximize killing, multiple 
treatments with new administrations of 
ALA may be necessary.
There is growing evidence that PDT 
can act as a biological response modi-
fier (BRM) and that its induction of host 
responses is an important contributor 
to short- and long-term outcomes in 
immunocompetent patients and ani-
mal models. Both innate and adaptive 
immune responses contribute to tumor 
killing. In brief, PDT is a broadly pro-
inflammatory event. Injured and dying 
cells in the treatment field release che-
mokines, cytokines, and chaperoned 
immunogenic proteins, and endothe-
lial cells express adhesion molecules 
(Gollnick et al., 2002; Gollnick et al., 
2003). HSP70 induced in oxidatively 
stressed or necrotic cells can stimu-
late toll-like receptors 2 and 4 (Asea 
et al., 2002). Although surviving but 
injured cells in the treatment field 
create an inflammatorily and immu-
nologically active milieu, repairable 
damage to their membrane receptors 
and signaling pathways may make 
them unresponsive to their environ-
ment for 24–48 hours (Liu, Oseroff et 
al., 2004); instead the milieu acts on 
newly arrived cells. In mouse models, 
the initial infiltrate is predominately 
neutrophils, followed by mast cells 
and macrophages (Krosl et al., 1995); 
natural killer (NK) cells also play a role 
(Korbelik, 1999). Antitumor efficacy is 
reduced by anti-neutrophil antibodies 
and in tumors implanted in nude or 
SCID mice (Korbelik et al., 1996).
There is also increasing evidence that 
PDT induces robust antitumor responses 
and generates tumor vaccines (Gollnick, 
2002; Korbelik and Sun, 2005). Existing 
protein antigens and neoantigens pro-
duced by oxidation or by the cross-
linking of adjacent membrane or cyto-
plasmic proteins (Liu, Oseroff et al., 
2004) can be bound and subsequently 
presented by PDT-induced stress pro-
tein chaperones such as HSP-70. PDT 
causes cell surface expression and 
release of HSPs (Korbelik et al., 2005). 
Lysates produced from PDT-treated 
tumor cells work without adjuvants to 
induce dendritic cell (DC) maturation 
and activate DCs to produce IL-12, 
which is critical to the development of 
a cellular immune response (Gollnick et 
al., 2002). In murine models Gollnick’s 
group recently has shown that PDT of 
a subcutaneous tumor generates tumor-
specific cytotoxic T cells (CTLs) that can 
eradicate existing metastatic disease 
as well as protect against subsequent 
tumor challenge. Optimal treatment 
conditions to maximize the effective-
ness of CTL generation are still being 
determined. PDT dose is important, but 
very high doses are less effective.
In NBCCS patients treated with wide-
area ALA-PDT over as much as 20% of 
body surface, we noted an unexpected 
durability of the clearing (Oseroff et al., 
2005), extending now as long as 7 years. 
This protection may be due to destruc-
tion of subclinical lesions, to induction 
of an antitumor response that suppresses 
development of new carcinomas, or to 
both processes. Evidence for an antitu-
mor response comes from an ongoing 
study of our BCC patients receiving ALA-
PDT in collaboration with Gollnick’s 
group. We find induction of CTL react-
ing with a HLA-A2 binding peptide 
generated from hedgehog interactive 
protein (HIP), expressed in BCC. All 13 
HLA-A2+ patients have had an increase 
in HIP-reactive CTLs ranging from 50% 
to 130% (unpublished data). This is con-
sistent with our anecdotal observation 
of regression of small, untreated BCCs 
in some patients after either ALA- or 
Photofrin-PDT treatment.
Given the role of innate and adaptive 
immunity in PDT, it is not surprising that 
ALA-PDT is less effective in immunosup-
pressed transplant recipients. In mouse 
models, repetitive ALA-PDT suppresses 
the development of SCC (Stender et al., 
1997; Liu, Viau et al., 2004). However, 
the mice were immunocompetent, and 
the relative contributions of destruction 
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of subclinical lesions versus induction 
of antitumor responses have not yet 
been defined.
Transplant recipients may have sig-
nificant morbidity and even mortal-
ity from their skin cancers, and no 
outstanding therapeutic options (Berg 
and Otley, 2002). For example, a 
recent trial of imiquimod in transplant 
recipients found only a 36% response 
rate of AK and a 50% improvement in 
atypia at the end of 16 weeks of treat-
ment (Brown et al., 2005). Thus, it 
seems worth pursuing further trials of 
ALA-PDT in which direct cell killing is 
aggressively optimized. Several steps 
can be taken to maximize efficacy. 
First, to ensure that ALA can penetrate 
the lesions, remove hyperkeratotic 
scale and crust using physical means 
(curettage, microdermabrasion, or even 
sandpaper) or keratolytics. Second, 
apply ALA for long enough to allow 
adequate PpIX synthesis at the level 
of the skin appendages; 4 hours is the 
minimum, 5–6 hours may be preferable 
(Morton et al., 1998). Third, use at least 
100 J/cm2 of red light (600–700 nm), 
along with an optical coupling medium 
such as mineral oil or a transparent gel 
if any hyperkeratosis or scale remains; 
red wavelengths have decreased scat-
tering and increased penetration com-
pared to blue. Fourth, because the PpIX 
may be photobleached before all target 
cells are killed, use multiple treatment 
sessions every 7–10 days as neces-
sary to achieve clinical reduction in 
AK; biopsy resistant lesions to rule out 
invasive SCC. Fifth, repeat treatments at 
6–12-month intervals as lesions recur 
or appear, while they are sparse, small 
and more responsive. Sixth, large-area, 
repetitive treatments are feasible only 
with adequate pain control. PDT-asso-
ciated pain scales with treatment area. 
For large-area, aggressive treatments, 
we use conscious sedation or even 
MAC anesthesia. The resulting lack of 
discomfort is transformative for patients 
and staff.
As a final note, PDT holds clear ther-
apeutic promise for immunocompe-
tent individuals who can benefit from 
both the cytotoxic and BRM arms of 
the treatment; the possibility of cancer 
prevention in at-risk patients through 
this in situ “vaccination” also warrants 
careful study. In general, the effects of 
PDT on the immune system have not 
been extensively studied by investiga-
tive dermatologists, though they are 
a superset of UVA-induced oxidative 
stress. In this era of “translational rel-
evance,” PDT could be a fertile site for 
both inquiry and funding.
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